Perkinil® Tablet : Each tablet contains Procyclidine Hydrochloride USP 5
Perkinil® Injection : Each 2 ml ampoule contains Procyclidine
Hydrochloride USP 10 mg.
Perkinil® (Procyclidine Hydrochloride) is an antimuscarinic
antiparkinsonian agent of relatively low toxicity. It is a synthetic tertiary
amine. This drug exerts their antiparkinsonian eect by correcting the
relative cholinergic excess which is thought to occur in parkinsonian as a
result of dopamine deciency. It is absorbed from G.I. tract and disappears
rapidly from the tissues. After intravenous administration, it acts within 5
to 20 minutes and has duration of eect upto 4 hours.
Perkinil® is used for the adjunctive treatment of all forms of parkinsonian
syndrome. It is mainly used for the symptomatic treatment of idiopathic
(paralysis agitants), postencephalitic and arteriosclerotic parkinsonian. It is
used to control troublesome extrapyramidal symptoms including pseudoparkinsonian, acute dystonic reactions and akathisia induced by
neuroleptic drugs such as phenothiazine derivatives.
DOSAGE & ADMINISTRATION
Perkinil® tablet is administered orally, preferably after meals.
Parkinsonism: Initially 2.5 mg 3 times a day, then 5 mg 3 times a day and
occasionally 5 mg at bed time. The dosage being adjusted as tolerated or
until the total daily dose reaches 20 to 30 mg divided into 3 to 4 doses.
Drug induced extrapyramidal symptom: Initially 2.5 mg 3 times a day. The
dosage being increased by 2.5 mg increment per day as needed and
By intramuscular or intravenous injection, 5-10 mg, repeated if necessary
after 20 minutes; maximum 20 mg daily can be given.
Children: Safety and ecacy have not been established in the pediatric age
group; therefore the use of Procyclidine hydrochloride is this group
requires that the potential benets be weighed against the possible
hazards to children.
It should be given with caution in children and geriatric patients. It is
advisable to be cautious in giving Procyclidine to patients with diarrhoea
and cardiovascular disease, glaucoma, urinary retention, hepatic or renal
At usual dosage levels dryness of the mouth is generally the only adverse
eect. Mydriasis, blurred vision and adverse G.I. eects (nausea, vomiting,
epigastric distress, constipation) occur occasionally. An allergic reaction
(e.g. rash) or muscular weakness may occasionally occur. High doses may
cause vertigo and possibly confusion and hallucination. Adverse eect
may usually be minimized by adjustment of dosage and administration
The anticholinergic activity of Procyclidine may be increased by agents
having anticholinergic amantadine. The absorption of ketoconazole may
be reduced by concomitant administration of procyclidine.
USE IN PREGNANCY & LACTATION
The safe use of this drug in pregnancy, lactation or in women of
childbearing age requires that the potential benets be weighed against
the possible hazards to the mother and child.
Protect from light and moisture, store below 250 C. Keep out of the reach
Perkinil® Tablet : Each box contains 200 tablets in blister pack.
Perkinil® Injection : Each box contains 1 ampoule in blister pack.
Brand: Square Pharmaceuticals Ltd